GlassScriptPhysician profile
Larissa Chaplia
NPI 1548222797
$3,674.78
in general payments reported to CMS, 2019-2025
16 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $308 · 2021: $479 · 2022: $401 · 2023: $683 · 2024: $769 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.30 |
| Education | $294.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,053.95 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $870.59 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $399.56 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $182.50 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $152.43 | 2019-2024 | Veltassa |
| Lilly USA, LLC | $143.50 | 2024 | Jardiance |
| Travere Therapeutics, INC. | $129.91 | 2023 | |
| Mallinckrodt Hospital Products INC. | $125.00 | 2023 | Terlivaz |
| Mallinckrodt Enterprises LLC | $123.05 | 2019 | |
| Exact Sciences Corporation | $117.69 | 2024-2025 | Cologuard Collection Kit |
| Recor Medical INC | $109.68 | 2025 | Paradise Ultrasound Renal Denervation System |
| Novartis Pharmaceuticals Corporation | $91.73 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.67 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.67 | 2021 | |
| Ardelyx, INC. | $21.84 | 2024 | Ibsrela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.01 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Chaplia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.